Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 127-07-1] Hydroxyurea

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0313
Brand:	MCE
CAS:	127-07-1

Overview

MDL	MFCD00007943
Molecular Weight	76.05
Molecular Formula	CH4N2O2
SMILES	O=C(N)NO

For research use only. We do not sell to patients.

8 Publications Citing Use of MCE

[1]Signal Transduct Target Ther. 2022 Oct 17;7(1):354.
[2]Nat Commun. 2022 Aug 16;13(1):4822.
[3]Cell Death Dis. 2020 Nov 12;11(11):976.
[4]Cell Death Dis. 2020 Jun 15;11(6):464.
[5]J Cell Mol Med. 2019 Oct;23(10):6797-6804.
[6]J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
[7]Arch Biochem Biophys. 2020 Nov 15;694:108601.
[8]Holistic Integrative Oncology. 13 October 2022.

Summary

Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase . Hydroxyurea shows anti-orthopoxvirus activity.

IC50 & Target

HIV-1

In Vitro

Hydroxyurea is used in a number of myeloproliferative, neoplastic, HIV, and non-hematological diseases ^[1] . Treatment of cells in primary culture with 30 μM hydroxyurea for 96 hours significantly increases the fractional HbF content. The ^G γ: ^A γ-globin mRNA is induced 0.30- to 8-fold in vitro ^[2] . Hydroxyurea has been shown to block HIV-1 reverse transcription and/or replication in quiescent peripheral blood mononuclear cells and macrophages ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Hydroxyurea therapy producs consistent reductions in WBC and ANC without improvement in anemia over 17 weeks. Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvement in anemia compared to vehicle treated sickle cell mice ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00025402	III. Medizinische Klinik Mannheim\|National Cancer Institute (NCI)	Leukemia	July 1997	Phase 3
NCT00613054	Annick Desjardins\|Novartis Pharmaceuticals\|AstraZeneca\|Duke University	Glioblastoma\|Gliosarcoma	November 2007	Phase 1
NCT01259856	Ronald Hoffman\|Myeloproliferative Disorders-Research Consortium\|National Cancer Institute (NCI)\|Roche Pharma AG\|Icahn School of Medicine at Mount Sinai	High Risk Polycythemia Vera\|High Risk Essential Thrombocythemia	September 2011	Phase 3
NCT00000602	National Heart, Lung, and Blood Institute (NHLBI)	Anemia, Sickle Cell\|Hematologic Diseases\|Hemoglobinopathies	April 1994	Phase 2
NCT00001818	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	HIV Infection	June 1999	Phase 1
NCT00002412	Triangle Pharmaceuticals\|NIH AIDS Clinical Trials Information Service	HIV Infections		Phase 2
NCT00809042	Shiraz University of Medical Sciences	β-Thalassemia Intermedia	June 2007	Phase 2
NCT01950585	National Heart, Lung, and Blood Institute (NHLBI)\|The Cleveland Clinic\|National Institutes of Health Clinical Center (CC)	Pulmonary Hypertension	September 6, 2013	Early Phase 1
NCT03442114	Children´s Hospital Medical Center, Cincinnati	Sickle Cell Anemia\|Children, Only	July 12, 2018	Not Applicable
NCT01976416	Indiana University\|Doris Duke Charitable Foundation\|Makerere University\|Mulago Hospital, Uganda\|Children´s Hospital Medical Center, Cincinnati	Sickle Cell Anemia\|Sickle Cell Disease\|Malaria	September 2014	Phase 3
NCT00004089	National Cancer Institute (NCI)	Head and Neck Cancer	August 1999	Phase 2
NCT02286154	Children´s Hospital Medical Center, Cincinnati	Anemia, Sickle Cell	October 2014	Not Applicable
NCT05434000	Barau Dikko Teaching Hospital	Sickle Cell Disease\|Stroke	November 6, 2021	Not Applicable
NCT04750707	Global Health Uganda LTD\|Columbia University\|University of Pittsburgh\|Emory University\|Mulago Hospital, Uganda\|Makerere University\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Sickle Cell Anemia in Children	March 9, 2021	Phase 3
NCT05142254	Vanderbilt University Medical Center	Priapism Due to Sickle Cell Disease	April 1, 2022	Phase 2
NCT00122980	St. Jude Children´s Research Hospital\|National Heart, Lung, and Blood Institute (NHLBI)	Hemochromatosis\|Cerebrovascular Accident\|Anemia, Sickle Cell\|Hematologic Diseases	October 2006	Phase 3
NCT03077542	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Disease	April 6, 2017	Phase 1\|Phase 2
NCT02149537	Loyola University\|University of Illinois at Chicago\|University of Ibadan	Sickle Cell Disease\|Sickle Cell Anemia	December 2014	Phase 4
NCT04116502	University of Birmingham\|Novartis\|MPN Voice\|National Cancer Institute, France	Polycythemia Vera	October 25, 2019	Phase 3
NCT00055874	Heidelberg University	Leukemia	June 2002	Phase 3
NCT05357482	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Anemia\|Beta Thalassemia	May 12, 2022	Phase 1\|Phase 2
NCT02675790	Vanderbilt University Medical Center\|Aminu Kano Teaching Hospital\|Murtala Muhammed Specialist Hospital	Sickle Cell Disease\|Sickle Cell Anemia\|Stroke	January 2017	Phase 3
NCT00004897	Northwestern University\|National Cancer Institute (NCI)	Esophageal Cancer	October 1999	Phase 2
NCT00175838	University of Cambridge\|Cambridge University Hospitals NHS Foundation Trust\|Institute of Cancer Research, United Kingdom	Thrombocythemia\|Myeloproliferative Disorder	July 1997	Not Applicable
NCT00462735	Johnny Kao\|Icahn School of Medicine at Mount Sinai	Head and Neck Cancer\|Cancer of the Pharynx\|Cancer of the Larynx\|Nose Neoplasms\|Paranasal Sinus Neoplasms\|Cancer of the Oral Cavity	February 2007	Phase 2
NCT03860844	Sanofi	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia	August 6, 2019	Phase 2
NCT02214407	Groupe Francophone des Myelodysplasies\|Janssen-Cilag Ltd.	MDS	October 14, 2014	Phase 3
NCT00008047	GERCOR - Multidisciplinary Oncology Cooperative Group\|National Cancer Institute (NCI)	Esophageal Cancer	August 1999	Phase 1\|Phase 2
NCT02556099	Children´s Hospital Medical Center, Cincinnati\|Caribbean Institute for Health Research (CAIHR)	Sickle Cell Anemia	August 2014	Phase 2
NCT04617028	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Myelofibrosis	February 5, 2021	Phase 3
NCT03463733	M.E. van Linde\|Massachusetts General Hospital\|Amsterdam UMC, location VUmc	Glioma\|Glioblastoma	March 2, 2018	Phase 1
NCT00890396	National Heart, Lung, and Blood Institute (NHLBI)	Anemia, Sickle Cell	September 2008
NCT01211938	Gustave Roussy, Cancer Campus, Grand Paris\|Ministry of Health, France	Squamous Cell Carcinoma	June 15, 2010	Phase 2\|Phase 3
NCT03511118	Duke University\|The Emmes Company, LLC\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Lactating Women on Select DOI\|Breastfed Infants of Mothers on Select DOI	October 4, 2018
NCT00613132	Annick Desjardins\|Novartis Pharmaceuticals\|Duke University	Glioblastoma\|Gliosarcoma	May 2005	Phase 1
NCT01103583	S. Andrea Hospital	Multiple Sclerosis	July 2011	Phase 2\|Phase 3
NCT03020615	St. Jude Children´s Research Hospital\|National Heart, Lung, and Blood Institute (NHLBI)	Sickle Cell Anemia	May 12, 2017	Phase 2
NCT00519701	Duke University	Sickle Cell Anemia	April 2002	Not Applicable
NCT00706810	University of Utah	Cancer\|Brain Cancer\|Meningioma	December 2007	Phase 2
NCT00485511	Kaohsiung Medical University Chung-Ho Memorial Hospital	Spinal Muscular Atrophy	June 2007	Phase 2\|Phase 3
NCT00001958	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health Clinical Center (CC)	Beta Thalassemia\|Hemoglobinopathy	December 1999	Phase 2
NCT01783990	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health (NIH)	Sickle Cell Anemia	October 2012
NCT03107182	University of Chicago	HPV-Related Squamous Cell Carcinoma\|HNSCC	June 27, 2017	Phase 2
NCT01506544	Children´s Mercy Hospital Kansas City\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Sickle Cell Anemia	December 2011	Phase 1
NCT00002869	Medical Research Council\|National Cancer Institute (NCI)	Leukemia	April 1995	Phase 3
NCT05062278	Hospital Universitario Dr. Jose E. Gonzalez	AML\|Hyperleukocytosis	July 26, 2021	Phase 2
NCT00006400	National Heart, Lung, and Blood Institute (NHLBI)	Hematologic Diseases\|Anemia, Sickle Cell	August 2000	Phase 3
NCT03634488	Vanderbilt University Medical Center\|Aminu Kano Teaching Hospital\|Murtala Muhammad Specialist Hospital	Sickle Cell Anemia\|Severe Acute Malnutrition	August 18, 2021	Phase 2
NCT01966731	Children´s Hospital Medical Center, Cincinnati\|Bristol-Myers Squibb	Sickle Cell Disease	June 2014	Phase 1\|Phase 2
NCT00336362	University of Washington\|National Heart, Lung, and Blood Institute (NHLBI)\|George Papanicolaou Hospital	Beta-Thalassemia	July 2006	Not Applicable
NCT03062501	Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti	Anemia, Sickle Cell\|Anemia; Sickle-Cell, With Crisis	November 2016	Phase 2
NCT02480608	University of Leipzig	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	April 2004	Phase 1\|Phase 2
NCT00000586	National Heart, Lung, and Blood Institute (NHLBI)	Anemia, Sickle Cell\|Hematologic Diseases\|Hemoglobinopathies	January 1992	Phase 3
NCT00978146	Children´s Hospital of Philadelphia	Desmoid Tumors\|Fibromatosis	October 2009	Phase 2
NCT00003172	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Gastric Cancer	December 1997	Phase 2
NCT02640573	Baylor College of Medicine\|The University of Texas Health Science Center, Houston	Hemoglobin SC Disease	October 12, 2015	Phase 2
NCT00154375	Novartis Pharmaceuticals\|Novartis	Glioblastoma Multiforme\|Astrocytoma	October 2004	Phase 3
NCT01387763	Thomas Stauffer Larsen\|Odense University Hospital	Polycythemia Vera\|Essential Thrombocythemia\|Primary Myelofibrosis	January 2012	Phase 3
NCT00002868	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Leukemia	January 1996	Phase 3
NCT01425307	Children´s Hospital Medical Center, Cincinnati\|National Heart, Lung, and Blood Institute (NHLBI)\|Boston Children´s Hospital\|University of Texas Southwestern Medical Center\|Children´s Healthcare of Atlanta\|Children´s Hospital of Philadelphia\|The Hospital for Sick Children\|Children´s National Research Institute\|Columbia University\|St. Jude Children´s Research Hospital\|University Hospitals Cleveland Medical Center\|University of South Alabama\|Medical University of South Carolina\|University of Alabama at Birmingham\|University of Miami\|University of Mississippi Medical Center\|Wayne State University\|Children´s Hospital of The King´s Daughters\|Nemours Children´s Clinic\|Duke University\|East Carolina University\|Children´s Hospitals and Clinics of Minnesota\|Ann & Robert H Lurie Children´s Hospital of Chicago\|Baylor College of Medicine\|State University of New York - Downstate Medical Center\|Steven and Alexandra Cohen Children´s Medical Center	Sickle Cell Anemia	August 2011	Phase 3
NCT00615927	Duke University\|Novartis Pharmaceuticals	Glioblastoma\|Gliosarcoma	February 2006	Phase 2
NCT00083187	Vion Pharmaceuticals\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	November 2005	Phase 2
NCT01693718	University of Chicago	Head and Neck	March 2003	Phase 2
NCT00002176	Bristol-Myers Squibb	HIV Infections	May 1997	Not Applicable
NCT05548062	Novartis Pharmaceuticals\|Novartis	Polycythemia Vera	February 14, 2023
NCT02088541	Karyopharm Therapeutics Inc	Acute Myeloid Leukemia (AML)	March 2014	Phase 2
NCT00019058	National Cancer Institute (NCI)	Brain and Central Nervous System Tumors	April 1995	Phase 1
NCT04217356	University Health Network, Toronto	Myelofibrosis\|High-Risk Cancer\|Bone Marrow Cancer	August 5, 2020
NCT01521299	Dartmouth-Hitchcock Medical Center	Advanced Solid Tumors	March 2012	Phase 1
NCT02899169	First Affiliated Hospital Xi´an Jiaotong University\|Tang-Du Hospital	Acute Promyelocytic Leukemia	September 1, 2016	Phase 3
NCT00383448	Masonic Cancer Center, University of Minnesota	Adrenoleukodystrophy\|Metachromatic Leukodystrophy\|Globoid Cell Leukodystrophy\|Tay Sachs Disease\|Sandhoffs Disease\|Wolman Disease\|I-Cell Disease\|Sanfilippo Syndrome\|GM1 Gangliosidosis	September 2006	Phase 2
NCT00006339	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 2
NCT05526924	University of Chicago	Head and Neck Cancer\|Head and Neck Squamous Cell Carcinoma\|Head and Neck Carcinoma\|Head and Neck Cancer Stage IV\|Head and Neck Cancers - Throat	November 1, 2022	Phase 1
NCT00002951	University of Chicago\|National Cancer Institute (NCI)	Esophageal Cancer\|Head and Neck Cancer	June 1996	Phase 2
NCT04707235	ADDMEDICA SASA\|International Clinical Trials Association	Sickle Cell Disease	August 21, 2020
NCT03944915	University of Chicago	Human Papilloma Virus\|Squamous Cell Carcinoma\|Squamous Cell Carcinoma of the Head and Neck\|HPV-Related Squamous Cell Carcinoma\|HNSCC	August 26, 2019	Phase 2
NCT02336373	Baylor College of Medicine	Hemoglobin SC Disease	December 2014	Phase 2
NCT03183375	Dr.Saqib Hussain Ansari\|Omair Sana Foundation	Thalassemia, Beta	August 21, 2017	Phase 2
NCT05470270	ADDMEDICA SASA	Sickle Cell Disease	July 8, 2022	Phase 2
NCT00004492	University of North Carolina\|FDA Office of Orphan Products Development	Sickle Cell Anemia	October 1999	Phase 1\|Phase 2
NCT02258659	University of Chicago\|National Cancer Institute (NCI)	Human Papilloma Virus Infection\|Stage III Squamous Cell Carcinoma of the Oropharynx\|Stage IVA Squamous Cell Carcinoma of the Oropharynx\|Stage IVB Squamous Cell Carcinoma of the Oropharynx	September 22, 2014	Phase 2
NCT00023959	National Cancer Institute (NCI)	Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma\|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity\|Recurrent Basal Cell Carcinoma of the Lip\|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity\|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity\|Recurrent Lymphoepithelioma of the Nasopharynx\|Recurrent Lymphoepithelioma of the Oropharynx\|Recurrent Metastatic Squamous Neck Cancer With Occult Primary\|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity\|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity\|Recurrent Salivary Gland Cancer\|Recurrent Squamous Cell Carcinoma of the Hypopharynx\|Recurrent Squamous Cell Carcinoma of the Larynx\|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity\|Recurrent Squamous Cell Carcinoma of the Nasopharynx\|Recurrent Squamous Cell Carcinoma of the Oropharynx\|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Recurrent Verrucous Carcinoma of the Larynx\|Recurrent Verrucous Carcinoma of the Oral Cavity\|Stage III Adenoid Cystic Carcinoma of the Oral Cavity\|Stage III Basal Cell Carcinoma of the Lip\|Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity\|Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity\|Stage III Lymphoepithelioma of the Nasopharynx\|Stage III Lymphoepithelioma of the Oropharynx\|Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity\|Stage III Mucoepidermoid Carcinoma of the Oral Cavity\|Stage III Salivary Gland Cancer\|Stage III Squamous Cell Carcinoma of the Hypopharynx\|Stage III Squamous Cell Carcinoma of the Larynx\|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage III Squamous Cell Carcinoma of the Nasopharynx\|Stage III Squamous Cell Carcinoma of the Oropharynx\|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Stage III Verrucous Carcinoma of the Larynx\|Stage III Verrucous Carcinoma of the Oral Cavity\|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity\|Stage IV Basal Cell Carcinoma of the Lip\|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity\|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity\|Stage IV Lymphoepithelioma of the Nasopharynx\|Stage IV Lymphoepithelioma of the Oropharynx\|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity\|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity\|Stage IV Salivary Gland Cancer\|Stage IV Squamous Cell Carcinoma of the Hypopharynx\|Stage IV Squamous Cell Carcinoma of the Larynx\|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage IV Squamous Cell Carcinoma of the Nasopharynx\|Stage IV Squamous Cell Carcinoma of the Oropharynx\|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Stage IV Verrucous Carcinoma of the Larynx\|Stage IV Verrucous Carcinoma of the Oral Cavity\|Untreated Metastatic Squamous Neck Cancer With Occult Primary	July 2001	Phase 1
NCT00354913	Duke University\|National Cancer Institute (NCI)\|Novartis Pharmaceuticals	Glioblastoma\|Gliosarcoma	May 2005	Phase 2
NCT00004901	Robert H. Lurie Cancer Center\|National Cancer Institute (NCI)	Head and Neck Cancer	October 1999	Phase 1\|Phase 2
NCT03715972	Children´s Hospital Los Angeles\|National Heart, Lung, and Blood Institute (NHLBI)\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|Vanderbilt University Medical Center	Thalassemia\|Sickle Cell Disease\|Healthy Controls	July 15, 2018
NCT00006119	UNICANCER	Brain and Central Nervous System Tumors	July 1999	Phase 2
NCT00180973	Gustave Roussy, Cancer Campus, Grand Paris	LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT	February 1995	Phase 3
NCT00000919	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Not Applicable
NCT02090296	Children´s National Research Institute	Sickle Cell Anemia	February 2014	Phase 2
NCT01801423	Vanderbilt University Medical Center\|National Institutes of Health (NIH)\|National Institute of Neurological Disorders and Stroke (NINDS)\|Aminu Kano Teaching Hospital	Sickle Cell Anemia\|Sickle Cell Disease\|Stroke	April 24, 2013	Not Applicable
NCT05132270	Children´s Hospital Karachi	Thalassemia, Beta	January 1, 2020	Phase 2\|Phase 3
NCT00344981	University of Maryland, Baltimore	HIV Infections\|AIDS	June 2003	Not Applicable
NCT00004094	National Cancer Institute (NCI)	Head and Neck Cancer	August 1999	Phase 2
NCT02611973	Assistance Publique - Hôpitaux de Paris	MPN\|Essential Thrombocythemia	March 10, 2016	Phase 3
NCT01531387	Children´s Hospital Medical Center, Cincinnati\|National Heart, Lung, and Blood Institute (NHLBI)\|St. Jude Children´s Research Hospital\|Tropical Medicine Research Institute\|Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti	Sickle Cell Anemia	May 2012	Phase 3
NCT05020652	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Moderate and High Risk Myelofibrosis	November 11, 2021	Phase 2
NCT01848925	Prolong Pharmaceuticals	Sickle Cell Disease	May 2013	Phase 1
NCT00000916	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 2
NCT00290771	Novartis	Recurrent Glioblastoma Multiforme (GBM)	February 2006	Phase 2
NCT01632904	Incyte Corporation	Polycythemia Vera	June 2012	Phase 3
NCT01964755	University of Miami	Epstein Barr Virus Associated Non Hodgkin´s Lymphoma\|Epstein Barr Virus Associated Hodgkin´s Lymphoma\|Post-Transplant Lymphoproliferative Disease	April 21, 2009	Phase 2
NCT00402480	Duke University	Stroke	April 2003	Phase 2
NCT00002177	Bristol-Myers Squibb	HIV Infections	May 1997	Not Applicable
NCT03763656	Nova Laboratories Limited	Sickle Cell Disease\|Sickle-Cell; Hemoglobin Disease, Thalassemia\|Sickle Cell-beta-thalassemia\|Sickle Cell Hemoglobin C	November 20, 2018	Phase 2
NCT00000939	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 2
NCT00002674	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Leukemia	October 1994	Phase 2
NCT00001074	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 1
NCT03651102	Blood Diseases Clinic\|University of Peshawar	Thalassemia	January 1, 2018	Phase 2\|Phase 3
NCT00270478	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Disease\|Chronic Kidney Disease\|Pulmonary Hypertension	December 21, 2005	Phase 1
NCT01949805	AOP Orphan Pharmaceuticals AG\|PharmaEssentia (Co-Sponsor for USA)	Polycythemia Vera	September 2013	Phase 3
NCT00005823	Leukemia Research Fund\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	December 1998	Phase 3
NCT00005018	Glaxo Wellcome\|NIH AIDS Clinical Trials Information Service	HIV Infections	July 1999	Phase 4
NCT05249452	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Sickle Cell Disease	March 8, 2018
NCT00008866	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 2
NCT02042222	Baylor College of Medicine\|Children´s Hospital Medical Center, Cincinnati	Sickle Cell Disease	October 2013	Early Phase 1
NCT02757885	Emory University	Sickle Cell Disease	April 2016	Phase 2
NCT00004933	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Leukemia	January 2000	Phase 3
NCT00904735	Istituto Scientifico H. San Raffaele\|National Cancer Institute (NCI)	Brain and Central Nervous System Tumors	June 2009	Phase 2
NCT00004404	Boston Children´s Hospital\|FDA Office of Orphan Products Development	Sickle Cell Anemia	April 1997	Not Applicable
NCT03644953	Children´s National Research Institute	Sickle Cell Disease	October 30, 2018	Phase 2
NCT02769845	Children´s Hospital Medical Center, Cincinnati\|Hospital Infantil Dr. Robert Reid Cabral	Sickle Cell Anemia	March 16, 2016	Not Applicable
NCT03500731	Paul Szabolcs\|University of Pittsburgh	Idiopathic Pulmonary Fibrosis\|Emphysema or COPD	April 19, 2018	Phase 1\|Phase 2
NCT00056433	National Institutes of Health Clinical Center (CC)	Sickle Cell Anemia	March 10, 2003	Phase 1
NCT04808778	Vanderbilt University Medical Center\|Aminu Kano Teaching Hospital	Sickle Cell Disease\|Sickle Cell Anemia\|Stroke, Ischemic\|Silent Stroke\|Silent Cerebral Infarct\|Stroke	May 17, 2021
NCT04126681	Ascentage Pharma Group Inc.\|HealthQuest Pharma Inc.	Chronic Myeloid Leukemia, Chronic Phase	October 21, 2019	Phase 2
NCT00002427	Research Institute for Genetic and Human Therapy\|NIH AIDS Clinical Trials Information Service	HIV Infections	May 1999	Phase 1
NCT03825341	St. Jude Children´s Research Hospital	Sickle Cell Disease\|Thalassemia	June 10, 2019	Phase 2
NCT00019474	Montefiore Medical Center\|National Cancer Institute (NCI)	Extrahepatic Bile Duct Cancer\|Gastric Cancer\|Gastrointestinal Carcinoid Tumor\|Liver Cancer\|Pancreatic Cancer\|Small Intestine Cancer	March 1998	Phase 2
NCT00468169	University of Chicago\|Bristol-Myers Squibb	Head and Neck Cancer	July 2006	Phase 2
NCT00002418	Bristol-Myers Squibb\|Boehringer Ingelheim\|Triangle Pharmaceuticals	HIV Infections		Phase 2
NCT03263559	Medical College of Wisconsin\|National Heart, Lung, and Blood Institute (NHLBI)\|National Cancer Institute (NCI)\|Blood and Marrow Transplant Clinical Trials Network\|National Marrow Donor Program	Sickle Cell Disease	October 3, 2017	Phase 2
NCT01065038	AOP Orphan Pharmaceuticals AG	Essential Thrombocythaemia	September 2002	Phase 3
NCT01624038	Ain Shams University	Thalassemia Intermedia	June 2012	Phase 2\|Phase 3
NCT00002940	St. Jude Children´s Research Hospital	Lymphoma	October 1996	Phase 2
NCT05405114	Novo Nordisk A+S	Sickle Cell Disease	July 7, 2022	Phase 2
NCT01711541	National Cancer Institute (NCI)	Head and Neck Squamous Cell Carcinoma\|Stage IVA Oropharyngeal Carcinoma AJCC v7\|Stage IVB Oropharyngeal Carcinoma AJCC v7	October 22, 2012	Phase 1\|Phase 2
NCT02225132	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Disease	August 23, 2014	Phase 1\|Phase 2
NCT03948867	Children´s Hospital Medical Center, Cincinnati\|Bugando Medical Centre\|The American Society of Hematology	Sickle Cell Anemia in Children	April 24, 2019	Phase 2
NCT00387933	Duke University\|National Cancer Institute (NCI)	Brain and Central Nervous System Tumors	July 2005	Phase 1
NCT05451940	Julia Xu\|Carnegie Mellon University\|American Society of Hematology\|University of Pittsburgh	Anemia, Sickle Cell\|Sickle Cell Disease	October 15, 2022	Phase 1\|Phase 2
NCT01847326	University of Chicago\|National Cancer Institute (NCI)	Recurrent Salivary Gland Cancer\|Recurrent Squamous Cell Carcinoma of the Hypopharynx\|Recurrent Squamous Cell Carcinoma of the Larynx\|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity\|Recurrent Squamous Cell Carcinoma of the Nasopharynx\|Recurrent Squamous Cell Carcinoma of the Oropharynx\|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Recurrent Verrucous Carcinoma of the Larynx\|Recurrent Verrucous Carcinoma of the Oral Cavity\|Salivary Gland Squamous Cell Carcinoma\|Tongue Cancer	March 26, 2013	Phase 1
NCT03515018	First Affiliated Hospital of Harbin Medical University	Leukemia, Chronic Myeloid	May 1, 2018	Phase 3
NCT01389024	Johns Hopkins University\|National Center for Research Resources (NCRR)\|Washington University School of Medicine\|Vanderbilt University School of Medicine\|University of Alabama at Birmingham\|Children´s Hospital of Philadelphia\|Medical University of South Carolina\|RTI International\|Columbia University\|Children´s Mercy Hospital Kansas City\|Sinai Hospital of Baltimore	Sickle Cell Disease\|Stroke	October 2011	Phase 2
NCT05285917	Brown University\|National Heart, Lung, and Blood Institute (NHLBI)\|Novartis	Sickle Cell Anemia in Children\|Sickle Cell Disease	December 1, 2022	Phase 3
NCT00568698	Stanford University	Muscular Atrophy, Spinal	January 2004	Phase 1\|Phase 2
NCT01962415	Paul Szabolcs\|University of Pittsburgh	Primary Immunodeficiency (PID)\|Congenital Bone Marrow Failure Syndromes\|Inherited Metabolic Disorders (IMD)\|Hereditary Anemias\|Inflammatory Conditions	February 4, 2014	Phase 2
NCT05005182	Mayo Clinic\|National Cancer Institute (NCI)	Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable	January 17, 2022	Phase 2
NCT00117572	University of Chicago	Cancer of the Pharynx\|Cancer of the Larynx\|Cancer of the Nasal Cavity\|Paranasal Sinus Neoplasms\|Cancer of the Oral Cavity	November 2004	Phase 3
NCT05025072	ADDMEDICA SASA\|Simbec-Orion Group\|Oncodesign SA\|PHINC DEVELOPMENT	Healthy Volunteers	August 22, 2021	Phase 1
NCT00002771	German CML Study Group\|National Cancer Institute (NCI)	Leukemia	January 1995	Phase 3
NCT00002230	Northwestern University\|NIH AIDS Clinical Trials Information Service	HIV Infections		Phase 3
NCT04292314	Beni-Suef University\|Maternity and Children Hospital, Makkah\|Beni-Suef Health insurance hospital\|University of Arizona	Iron Overload\|Oxidative Stress\|Thalassemia Major	November 1, 2019	Phase 2\|Phase 3
NCT00350844	Ann & Robert H Lurie Children´s Hospital of Chicago	Sickle Cell Disease\|Pulmonary Hypertension	July 2006	Phase 1\|Phase 2
NCT03128515	Indiana University\|Doris Duke Charitable Foundation\|Makerere University\|Mulago Hospital, Uganda\|Children´s Hospital Medical Center, Cincinnati	Sickle Cell Anemia\|Sickle Cell Disease\|Malaria	July 26, 2017	Phase 3
NCT02844673	Muhimbili University of Health and Allied Sciences\|University of Pittsburgh\|Muhimbili National Hospital	Sickle Cell Anaemia	October 2016	Phase 4
NCT01645124	Consorzio Mario Negri Sud\|Agenzia Italiana del Farmaco\|A.O. Ospedale Papa Giovanni XXIII	Polycythemia Vera	May 2008	Phase 3
NCT00202644	Shire\|Takeda	Thrombocythemia, Hemorrhagic	January 13, 2006	Phase 4
NCT00784082	Assistance Publique - Hôpitaux de Paris	Sickle Cell Disease	May 2009
NCT00143572	St. Jude Children´s Research Hospital	Anemia, Sickle Cell	November 2004	Phase 1
NCT00928707	Italfarmaco	Polycythemia Vera	June 2009	Phase 2
NCT00001197	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Anemia	February 7, 1984	Phase 2
NCT00568802	Stanford University	Muscular Atrophy, Spinal	January 2004	Phase 1\|Phase 2
NCT03653338	Paul Szabolcs\|University of Pittsburgh	Sickle Cell Anemia\|Beta-thalassemia Major\|Diamond-blackfan Anemia	August 2, 2018	Phase 1\|Phase 2
NCT05081349	Assiut University	Sickle Cell Disease	January 10, 2017	Phase 4
NCT03789591	Children´s Hospital Medical Center, Cincinnati\|Doris Duke Charitable Foundation	Sickle Cell Disease\|Sickle Cell Anemia	January 17, 2019	Phase 3
NCT00002887	Ottawa Regional Cancer Centre\|National Cancer Institute (NCI)	Lung Cancer	July 1995	Phase 1
NCT01960413	Vanderbilt University Medical Center\|Medical College of Wisconsin\|Versiti	Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)	November 2013	Phase 2
NCT00532883	St. Jude Children´s Research Hospital\|National Heart, Lung, and Blood Institute (NHLBI)	Hemoglobin SC Disease	January 2007	Phase 2
NCT03806452	ADDMEDICA SASA	Sickle Cell Disease	May 28, 2019	Phase 2
NCT00002420	Bristol-Myers Squibb\|Pharmacia and Upjohn\|Triangle Pharmaceuticals	HIV Infections		Phase 2
NCT00003590	Southwest Oncology Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Adult Meningioma	November 1998	Phase 2
NCT02560935	Vanderbilt University Medical Center\|Aminu Kano Teaching Hospital\|Murtala Muhammed Specialist Hospital\|National Institute of Neurological Disorders and Stroke (NINDS)\|Barau Dikko Teaching Hospital+Kaduna State University	Sickle Cell Disease\|Stroke	July 19, 2016	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 1314.92 mM ; Need ultrasonic)

H ₂ O : 50 mg/mL ( 657.46 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	13.1492 mL	65.7462 mL	131.4924 mL
5 mM	2.6298 mL	13.1492 mL	26.2985 mL
10 mM	1.3149 mL	6.5746 mL	13.1492 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (1314.92 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31.
[2] Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92.
[3] Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7.
[4] Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603.
[5] M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60(2):506-14.

Synonyms

Urea, N-hydroxy-

Urea, hydroxy-

N-Hydroxyurea

SQ 1089

NSC 32065

Carbamohydroxamic acid

Hydrea

Hydroxycarbamide

Hydroxylurea

Hydroxyurea

Hydroxylamine, N-(aminocarbonyl)-

Carbamoyl oxime

Carbamohydroximic acid

Hydroxycarbamine

Litaler

Oxyurea

Hidrix

Hydreia

Hydura

Litalir

Onco-Carbide

Biosupressin

NCI C04831

N-Carbamoylhydroxylamine

Hydurea

SK 22591

Oxyrea

Droxia

Cytodrox

Siklos

Mylocel

1-Hydroxyurea

Xromi

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart